Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radio...
Main Authors: | Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst, Dirk Schadendorf |
---|---|
Format: | Article |
Language: | English |
Published: |
Medical Journals Sweden
2022-04-01
|
Series: | Acta Dermato-Venereologica |
Subjects: | |
Online Access: | https://medicaljournalssweden.se/actadv/article/view/293 |
Similar Items
-
Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity
by: Massimiliano Scalvenzi, et al.
Published: (2020-04-01) -
Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects
by: András Bánvölgyi, et al.
Published: (2020-05-01) -
Gorlin Syndrome: Sequential Digital Dermoscopy of Palpebral Basal Cell Carcinomas in a Patient Treated With Vismodegib
by: Luis Mena-Vergara, et al.
Published: (2022-02-01) -
Basal cell cancer treatment. Therapeutic experience with vismodegib therapy
by: N. N. Petenko, et al.
Published: (2018-07-01) -
Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion
by: Joseph Dodson, et al.
Published: (2022-12-01)